Essentials of SGLT2 Inhibitors in Diabetes
Autor Miles Fisher, Gerard McKayen Limba Engleză Paperback – 23 noi 2016
Preț: 320.73 lei
Preț vechi: 337.62 lei
-5% Nou
Puncte Express: 481
Preț estimativ în valută:
61.40€ • 63.82$ • 50.91£
61.40€ • 63.82$ • 50.91£
Carte tipărită la comandă
Livrare economică 01-07 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319432946
ISBN-10: 331943294X
Pagini: 56
Ilustrații: XI, 68 p. 13 illus. in color.
Dimensiuni: 127 x 203 x 7 mm
Greutate: 0.12 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland
ISBN-10: 331943294X
Pagini: 56
Ilustrații: XI, 68 p. 13 illus. in color.
Dimensiuni: 127 x 203 x 7 mm
Greutate: 0.12 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Adis
Locul publicării:Cham, Switzerland
V-ar putea interesa
-
Heart Disease and DiabetesMiles Fisher-16%Preț: 247.29 lei293.83 lei -
Diabetes Cookbook For DummiesA Rubin-5%Preț: 118.37 lei124.59 lei -
Prediabetes For DummiesAL Rubin-5%Preț: 116.21 lei122.33 lei -
Diabetes For Dummies 3e (UK Edition)S Jarvis-5%Preț: 118.37 lei124.59 lei -
Painful Diabetic Neuropathy in Clinical PracticeAndrew J.M. Boulton-5%Preț: 348.09 lei366.41 lei -
Diabetes and Hypertension: Evaluation and ManagementSamy I. McFarlane-5%Preț: 1313.73 lei1382.87 lei -
Gestational Diabetes During and After PregnancyCatherine Kim-5%Preț: 717.40 lei755.16 lei -
Understanding DiabetesScientific Publishing-5%Preț: 53.77 lei56.61 lei -
Managing Diabetic Eye Disease in Clinical PracticeRishi P Singh-5%Preț: 351.14 lei369.62 lei
Cuprins
Overview of Type 2 Diabetes.- SGLT2 Inhibitors for Treating Diabetes.- Guidelines for the Treatment of Type 2 Diabetes Mellitus.- Using SGLT2 Inhibitors in Special Populations.
Notă biografică
Professor Miles Fisher graduated from the University of Glasgow in 1979, where he received his MD in 1988 for his thesis on ‘Evidence for a Diabetic Cardiopathy.’ He has been a consultant physician at Glasgow Royal Infirmary since 2001. In 2010, he was made an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-2014. Professor Fisher is the current President of the Scottish Society of Physicians. He interests include diabetes and the heart, hypoglycemia, and new treatments for diabetes, and he is the author or co-author of over 70 original papers, over 60 review articles, and over 40 book chapters. He was on the steering committee of the DIGAMI 2 study as the Scottish coordinator, as well as an events adjudicator for the HOPE and HOPE-TOO studies, and is currently an events adjudicator for the ACE Trial.
Professor Gerald (Gerry) McKay studied medicine at the University of Glasgow with subsequent training in the west of Scotland before undertaking specialty training in clinical pharmacology and therapeutics in Newcastle upon Tyne. Additional specialty training included specific training in diabetes and cardiovascular risk management. As an Association of the British Pharmaceutical Industry (ABPI)-sponsored trainee, Professor McKay spent a year in industry with Pfizer gaining experience in all aspects of drug development. He also had a secondment to the National Institute for Health and Clinical Excellence (NICE). After 3 years as a consultant in a busy district general hospital, in 2007 Professor McKay became a Consultant Physician and Clinical Pharmacologist at Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow with a specialist interest in type 2 diabetes and diabetic nephropathy, as well as an interest in safe and rational prescribing. He has considerable commitment to undergraduate and postgraduate education at the University of Glasgow and University of Strathclyde where he holds honorary positions. Additionally, he is Vice Chair of NHS Greater Glasgow and Clyde’s Area Drug and Therapeutics committee and served for 7 years on the New Drugs Committee of the Scottish Medicines Consortium. Professor McKay is the co-editor of a major undergraduate textbook on clinical pharmacology and has published numerous papers in the field of diabetes and therapeutics.
Professor Gerald (Gerry) McKay studied medicine at the University of Glasgow with subsequent training in the west of Scotland before undertaking specialty training in clinical pharmacology and therapeutics in Newcastle upon Tyne. Additional specialty training included specific training in diabetes and cardiovascular risk management. As an Association of the British Pharmaceutical Industry (ABPI)-sponsored trainee, Professor McKay spent a year in industry with Pfizer gaining experience in all aspects of drug development. He also had a secondment to the National Institute for Health and Clinical Excellence (NICE). After 3 years as a consultant in a busy district general hospital, in 2007 Professor McKay became a Consultant Physician and Clinical Pharmacologist at Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow with a specialist interest in type 2 diabetes and diabetic nephropathy, as well as an interest in safe and rational prescribing. He has considerable commitment to undergraduate and postgraduate education at the University of Glasgow and University of Strathclyde where he holds honorary positions. Additionally, he is Vice Chair of NHS Greater Glasgow and Clyde’s Area Drug and Therapeutics committee and served for 7 years on the New Drugs Committee of the Scottish Medicines Consortium. Professor McKay is the co-editor of a major undergraduate textbook on clinical pharmacology and has published numerous papers in the field of diabetes and therapeutics.
Jenna L Cowan, MbChB, BSc (Med Sci), MRCP has been a specialty registrar in Diabetes and Endocrinology in the West of Scotland Deanery since 2008. She qualified from the University of Glasgow in 2004 and is currently completing her final specialty training at the Queen Elizabeth University Hospital in Glasgow. Her clinical interests include genetic and gestational diabetes.
Caracteristici
Ideal for medical professionals wishing to expand their knowledge about a SGLT2 inhibitors, a novel drug class for the treatment of diabetes Written by experts in the field, this handbook includes only the most clinically relevant information to support direct application to patient care Includes evidence-based guidelines, major clinical trials, and the range of treatment options currently available or in development